** Shares of drug developer Summit Therapeutics SMMT.O rise 3% to $23.30
** AstraZeneca AZN.L is in talks to partner with Summit for up to $15 billion to license a lung cancer drug, ivonescimab, Bloomberg news reported, citing people familiar with the matter
** Summit is also talking to other major pharmaceutical companies about potential partnerships, the report said
** Summit did not immediately respond to Reuters' request seeking comment while an AstraZeneca spokesperson declined to comment
** Including session's move, stock up 25.6% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.